Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Target Recruit Count
- 40
- Registration Number
- NCT01021943
- Locations
- 🇲🇽
Instituto Nacional Nutricion Salvador Zubiran, Mexico, Mexico
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
- Conditions
- Myocardial FibrosisHypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT00879060
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Aldosterone in Diabetic Nephropathy
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Universidad de los Andes, Chile
- Target Recruit Count
- 160
- Registration Number
- NCT00870402
- Locations
- 🇨🇱
University of Los Andes, Santiago, Chile
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
- Conditions
- Type 2 Diabetes MellitusVascular Disease
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT00865124
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 50
- Registration Number
- NCT00865501
- Locations
- 🇩🇪
University Erlangen-Nürnberg, Nephrology and Hypertension, Erlangen, Germany
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Target Recruit Count
- 20
- Registration Number
- NCT00865449
- Locations
- 🇲🇽
Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico
Hemodynamic Effects of Spironolactone in Patients With Heart Failure
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- University of Toledo Health Science Campus
- Target Recruit Count
- 18
- Registration Number
- NCT00860340
- Locations
- 🇺🇸
Medical University of Ohio, Toledo, Ohio, United States
The Effect of Amiloride and Spironolactone in Healthy Persons
- Conditions
- High Blood Pressure
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 30
- Registration Number
- NCT00857909
- Locations
- 🇩🇰
Medical Research, Holstebro, Denmark
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Drug: Oral contraceptive plus metforminDrug: oral contraceptive
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 75
- Registration Number
- NCT00842140
- Locations
- 🇧🇷
University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
- Conditions
- Right Heart FailurePulmonary Hypertension
- Interventions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT00811486
- Locations
- 🇺🇸
University of Colorado at Denver and Health Sciences Center General Clinical Research Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.